ACADIA Pharmaceuticals Inc. vs Prologis Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Prologis Inc trades at $139.07 (market cap $132.57B). The key difference: Prologis Inc is far larger — about 26.1× ACADIA Pharmaceuticals Inc.'s market cap, and Prologis Inc pays a 3.07% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PLD | |
|---|---|---|
Market Cap | $5.07B | $132.57B |
Sector | Health | Real Estate |
52-Week High | $29.41 | $149.96 |
52-Week Low | $20.06 | $104.81 |
Enterprise Value | $4.19B | $167.31B |
Dividend Yield | — | 3.07% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →